Table 1.
Circadian behavioral data for all genotypes tested.
| Circadian Parameter and Genotype | n | Before Tamoxifen | After Tamoxifen | p Value | Adjusted p Value |
|---|---|---|---|---|---|
| τDD (hours) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 7 | 23.72 ± 0.09 | 22.66 ± 0.15 | 0.0001 | 0.0045 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 23.76 ± 0.03 | 23.74 ± 0.05 | 0.7968 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 8 | 23.75 ± 0.02 | 23.73 ± 0.11 | 0.8102 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 23.76 ± 0.04 | 23.78 ± 0.04 | 0.8155 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 23.69 ± 0.09 | 23.74 ± 0.04 | 0.4852 | 1.0000 |
| Amplitude (AU) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 7 | 5272 ± 636 | 3658 ± 646 | 0.0034 | 0.1530 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 5284 ± 361 | 5568 ± 541 | 0.4964 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 8 | 5405 ± 517 | 6165 ± 614 | 0.1459 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 4218 ± 320 | 4830 ± 320 | 0.1666 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 4571 ± 423 | 5789 ± 656 | 0.0076 | 0.3420 |
| Activity in light phase (%) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 10 | 6.79 ± 1.02 | 11.32 ± 2.01 | 0.0135 | 0.6075 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 4.51 ± 1.04 | 5.25 ± 1.50 | 0.8215 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 10 | 8.81 ± 1.99 | 5.98 ± 1.67 | 0.1141 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 10.17 ± 1.99 | 6.10 ± 1.03 | 0.0253 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 6.46 ± 1.32 | 3.69 ± 0.98 | 0.1236 | 1.0000 |
| ϕ (degrees) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 10 | 179 ± 0.9 | 169 ± 7.1 | 0.0055 | 0.2475 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 175 ± 3.7 | 172 ± 7.5 | 0.3587 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 9 | 175 ± 5.1 | 176 ± 4.0 | 0.9868 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 179 ± 0.7 | 181 ± 0.5 | 0.6193 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 180 ± 0.7 | 181 ± 0.6 | 0.8466 | 1.0000 |
| αLD (hours) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 10 | 12.09 ± 0.14 | 11.59 ± 0.52 | 0.0796 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 12.10 ± 0.16 | 11.85 ± 0.14 | 0.3470 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 9 | 12.22 ± 0.22 | 12.03 ± 0.13 | 0.4906 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 12.11 ± 0.17 | 12.07 ± 0.09 | 0.8707 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 11.93 ± 0.12 | 11.86 ± 0.10 | 0.8508 | 1.0000 |
| αDD (hours) | |||||
| Zfhx3Flox/Flox;UBC-Cre+ | 10 | 12.20 ± 0.82 | 10.73 ± 1.26 | 0.0229 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre+ | 11 | 12.84 ± 0.27 | 13.22 ± 0.23 | 0.5089 | 1.0000 |
| Zfhx3Flox/Flox;UBC-Cre− | 8 | 13.64 ± 0.39 | 13.08 ± 0.39 | 0.5556 | 1.0000 |
| Zfhx3Flox/+;UBC-Cre− | 10 | 12.67 ± 0.24 | 12.77 ± 0.21 | 0.8686 | 1.0000 |
| Zfhx3+/+;UBC-Cre+ | 10 | 12.68 ± 0.19 | 12.27 ± 0.18 | 0.4978 | 1.0000 |
τDD = period in constant darkness; AU = arbitrary units; ϕ = phase angle of entrainment in light-dark (180° denotes a phase angle consistent with a ZT12 activity onset); αLD = activity duration in light-dark; αDD = activity duration in constant darkness. Both unadjusted and adjusted p values are shown for pairwise comparisons of group data before and after tamoxifen treatment; Bonferroni adjustment was used for correction of multiple comparisons. Units of measurement for parameters refer to measurements before and after tamoxifen administration, expressed as mean ± standard error of the mean.